TD Cowen lowered the firm’s price target on DarioHealth to $3 from $5 and keeps a Buy rating on the shares. The firm said despite revenue coming in below expectations management is confident it can see 50% B2B2C growth in 2H driven by a more focused commercial approach and increasing customers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRIO:
- DarioHealth reports Q2 EPS 8c, consensus (55c)
- DarioHealth Reports Second Quarter 2024 Financial and Operating Results
- DRIO Earnings this Week: How Will it Perform?
- DarioHealth expands GLP-1 solution client base with new employer contract
- DarioHealth Shareholders Approve Equity Plan Expansion and Twill Acquisition Terms